Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973487 · ClinicalTrials.gov registry record · Phase 1
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Melanoma, sponsored by TScan Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 840
- Enrollment target
- 20
- Study locations
NCT05973487: Active Phase 1 study of Ovarian Cancer and Melanoma, sponsored by TScan Therapeutics.
NCT05973487 is a Phase 1 study of Ovarian Cancer and Melanoma that is active but no longer recruiting, run by TScan Therapeutics. The registered enrollment target is 840 participants, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05973487, a Phase 1 study of Ovarian Cancer and Melanoma, is active but no longer recruiting, sponsored by TScan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 840 participants
- Enrollment target
- 20
- Study locations
Study Summary
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.
Primary Outcome
Number of subjects with dose limiting toxicities (DLT)
Conditions Studied
Interventions
- BIOLOGICAL TSC-204-A0201
- BIOLOGICAL TSC-204-C0702
- BIOLOGICAL TSC-200-A0201
- BIOLOGICAL TSC-204-A0201 + TSC-204-C0702
- BIOLOGICAL TSC-204-A0201 + TSC-200-A0201
Study Locations (20)
Florida
- Memorial Healthcare System - Hollywood
- University of Miami, Sylvester Comprehensive Cancer Center - Miami
- Orlando Health - Orlando
- University of South Florida - Tampa
Ohio
- Oncology Hematology Care - Cincinnati
- The Cleveland Clinic - Cleveland
Pennsylvania
- Allegheny Hospitals Network - Pittsburgh
- University of Pittsburgh Medical Center - Pittsburgh
Arizona
- HonorHealth Research and Innovation Institute - Scottsdale
California
- University of California San Diego - San Diego
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago - Chicago
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2024-05-06 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 1 |
What the registry record for NCT05973487 still lists
NCT05973487 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, above the 726-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (16% higher).
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which TSC-204-A0201 is the first listed.
NCT05973487 names 20 study sites across 15 states, led by Florida, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05973487 about?
NCT05973487 is a clinical study titled "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors". TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a...
What is the current status of trial NCT05973487?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 840 participants. The study started on 2024-05-06. Estimated completion is 2026-12-30.
What conditions does trial NCT05973487 study?
This clinical trial studies the following conditions: Ovarian Cancer, Melanoma, Head and Neck Cancer, Cervical Cancer, HPV-Related Carcinoma.
What interventions are being tested in trial NCT05973487?
The interventions under investigation include: TSC-204-A0201 (BIOLOGICAL), TSC-204-C0702 (BIOLOGICAL), TSC-200-A0201 (BIOLOGICAL), TSC-204-A0201 + TSC-204-C0702 (BIOLOGICAL), TSC-204-A0201 + TSC-200-A0201 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05973487?
This trial is sponsored by TScan Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973487 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05973487's enrollment target sits among peer trials
840 30th of 322 higher than 293 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI